Neuromodulation and Language Acquisition (Stage Ib)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00102856 |
Recruitment Status :
Suspended
First Posted : February 4, 2005
Last Update Posted : June 24, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Pramipexole Drug: Rivastigmine | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Neuromodulation and Language Acquisition (KS-Neuromod_01, Stage Ib) |
Study Start Date : | January 2005 |
Study Completion Date : | June 2006 |

- Boost in language learning success (percent hits) through neuromodulation
- Stability of language learning success after one week, one month, and one year

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 35 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy subjects
- 20-35 years old
- Right handedness
- Left language dominance (as assessed by functional transcranial Doppler ultrasonography [fTCD])
Exclusion Criteria:
- Neurological/psychiatric/metabolic/cardiac disorders
- Asthma
- Known allergic reactions to one of the experimental drugs
- Other drugs affecting the central nervous system
- Leisure drug ingestion during the past 4 weeks (urine test)
- Smoking cessation during the past 2 weeks
- > 6 cups of coffee or energy drinks per day
- > 10 cigarettes per day
- > 50 grams of alcohol per day

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00102856
Germany | |
Dept. of Neurology, University Hospital Muenster | |
Muenster, Nordrhein-Westfalen, Germany, 48129 |
Study Director: | Caterina Breitenstein, PhD | Dept. of Neurology, University Hospital Muenster | |
Study Chair: | Stefan Knecht, MD | Dept. of Neurology, University Hospital Muenster |
Publications:
ClinicalTrials.gov Identifier: | NCT00102856 |
Other Study ID Numbers: |
KS-NEUROMOD_01, Stage Ib IZKF Muenster: Kne3/074/04 |
First Posted: | February 4, 2005 Key Record Dates |
Last Update Posted: | June 24, 2010 |
Last Verified: | September 2006 |
language acquisition plasticity stroke recovery associative learning |
Pramipexole Rivastigmine Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antiparkinson Agents Anti-Dyskinesia Agents |
Dopamine Agonists Dopamine Agents Neurotransmitter Agents Cholinesterase Inhibitors Enzyme Inhibitors Cholinergic Agents Neuroprotective Agents |